You are leaving the ̽»¨ÊÓÆµ website. By clicking this link, you will be taken to a website that is independent from ̽»¨ÊÓÆµ. The site you are linking to is not controlled or endorsed by ̽»¨ÊÓÆµ and ̽»¨ÊÓÆµ is not responsible for the content provided on that site.
̽»¨ÊÓÆµ is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat cancer patients.
With proven leadership and therapeutic radiopharmaceutical expertise, ̽»¨ÊÓÆµ has a strong pipeline of precision targeted radiopharmaceuticals. The initial focus is on prostate cancer with plans to expand to additional cancer types.
The approach of ̽»¨ÊÓÆµ is to build on the progress seen with first generation radiopharmaceuticals with unique, targeted radio hybrid agents.